by myNEO Tx Admin | Mar 8, 2024 | News
Today, on #internationalwomensday , we’re proud to celebrate the remarkable women of myNEO Therapeutics. Their talent, dedication, and leadership are at the heart of our success. Thank you for your invaluable contributions! #womeninhealthcareby myNEO Tx Admin | Feb 15, 2024 | News
Last week, our team came together for an engaging and informative training session about the cloud-based version of our ImmunoEngine led by Lore Van Oudenhove and Steve Lefever. These training sessions demonstrate our dedication to continuous improvement and knowledge...by myNEO Tx Admin | Nov 16, 2023 | Article, News
myNEO Therapeutics has been quite active in recent months, taking part in various conference presentations and participating in panel discussions. Additionally, we’re pleased to announce that our CEO, Cedric, received the Medical Genetics award at the Vexillum...The process starts with the collection of both patient blood and a tumor biopsy.
Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.
Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called 'neoX'.
Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides
In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).